A phase I study of a combination of yttrium-90-labeled anti-carcinoembryonic antigen (CEA) antibody and gemcitabine in patients with CEA-producing advanced malignancies.

Shibata, Stephen; Raubitschek, Andrew; Leong, Lucille; Koczywas, Marianna; Williams, Lawrence; Zhan, Jiping; Wong, Jeffrey Y C

Shibata, Stephen; Raubitschek, Andrew; Leong, Lucille; Koczywas, Marianna; Williams, Lawrence; Zhan, Jiping; Wong, Jeffrey Y C.

Affiliation

Shibata S; City of Hope, Duarte, California 91010, USA. sshibata@coh.org

Clin Cancer Res ; 15(8): 2935-41, 2009 Apr 15.

Article in En | MEDLINE | ID: mdl-19351765

Subject(s)

Antibodies, Monoclonal/therapeutic use; Carcinoembryonic Antigen/immunology; Deoxycytidine/analogs & derivatives; Gastrointestinal Neoplasms/drug therapy; Organometallic Compounds/therapeutic use; Aged; Antibodies, Monoclonal/adverse effects; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine/adverse effects; Deoxycytidine/therapeutic use; Female; Humans; Male; Middle Aged; Organometallic Compounds/adverse effects; Treatment Outcome; Gemcitabine

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Organometallic Compounds / Carcinoembryonic Antigen / Deoxycytidine / Gastrointestinal Neoplasms / Antibodies, Monoclonal Limits: Aged / Female / Humans / Male / Middle aged Language: En Journal: Clin Cancer Res Journal subject: NEOPLASIAS Year: 2009 Type: Article Affiliation country: United States

Fulltext

XML

PubMed Links

Search on Google